Introduction
The complement system is a major component of innate immunity (1) and plays central roles in protective immune processes, including pathogen clearance, recognition of foreign antigens, amplification of humoral and cellular immunity, removal of apoptotic cells and debris, and promotion of organogenesis and regeneration of certain tissues such as the liver following transplantation (2, 3) . In contrast, inappropriate complement activation directed against self tissues underlies the pathogenesis of a number of human inflammatory and autoimmune diseases. The successful development of complement therapeutics, as well as the presence of a substantial pipeline of drugs under development (4), has advanced opportunities for the application of complement therapeutics to rheumatic and inflammatory diseases. In this review, we will briefly describe the complement system and then focus on 1) emerging understanding of the pathogenic roles of complement activation in rheumatic and closely related diseases, and 2) updating contemporary complement pathway testing methodologies to answer questions regarding use of this approach in clinical settings and therapeutic development programs.
Initiation, amplification, regulation, and effector pathways in the complement system Activation. The complement system comprises 3 activation pathways: classical, alternative, and lectin ( Figure 1 ). The classical pathway is initiated through antibody-dependent and antibody-independent means, which act as the "targeting" mechanism to direct the powerful effector arms of complement to specific sites (5) . IgM and IgG antibodies activate the classical pathway, while IgA can activate the alternative pathway, and IgE is not an effective complement-activating isotype. Following antigen recognition and binding by C1q of the tripartite C1 complex, autocatalytic activation of C1r and transactivation of C1s result in the latter molecule sequentially cleaving C4 and C2 into C4b and C2a, respectively. These 2 proteins associate noncovalently as the classical pathway C3 convertase C4b2a. Antibody-independent classical pathway activators, which may be particularly important when products of tissue damage are elaborated, include the pentraxin Creactive protein as well as b-amyloid fibrils, and mitochondrial proteins; each of these molecules directly interacts with C1q and activates C1r/C1s. C1q also exhibits additional functions involving the clearance of apoptotic debris and regulation of synaptic pruning (6) .
The lectin pathway is initiated using different target recognition molecules designated collectins, a family that includes mannose-binding lectin (MBL), ficolins 1-3, and collectins 10-11, and is involved in protective clearance through the recognition of invariant features of foreign organisms (7) . The lectin pathway is also engaged during tissue injury through the direct recognition of proteins such as cytokeratin 1 and other less well characterized ligands, as well as IgM/IgG antibodies containing agalactosyl carbohydrates (8) . As in the classical pathway, connectivity to downstream generation of C3 and C5 convertases occurs through the engagement and conformationdependent elaboration of proteases, here MBL-associated serine protease 1 (MASP-1), MASP-2, and Figure 1 . Overview of complement system pathways and targets of complement therapeutics. The 3 complement activation pathways, and regulatory factors that control them, as illustrated through processes initiated on pathogens by binding of antibodies and lectin pathway recognition molecules. Cells are normally protected against these processes; however, when activation is excessive, damage ensues, and additional downstream inflammatory molecules are generated. Thick green X symbols indicate the sites where complement therapeutic inhibitors are focused. C1-INH = C1 esterase inhibitor; FB = factor B; MASP-1 = mannose-binding lectin-associated serine protease 1; sC5b-9 = soluble C5b-9; MAP-1 = mannose-binding lectin/ficolin-associated protein 1.
MASP-3, that cleave and activate C4, C2, and possibly C3 directly.
The alternative pathway, in contrast, is unique in being initiated through spontaneous conformational changes of C3 in a process designated "tick-over," which results in binding of factor B and cleavage by factor D, stabilization (and in some settings directed focusing) through properdin binding, and the ultimate formation of the C3 initiation convertase C3(H 2 O)BbP (9) . This process is accelerated through the binding of C3 to surfaces including gas bubbles, platelet surfaces, biomaterials, and microparticles as well as a convertase-stabilizing autoantibody designated C3 nephritic factor and some immunoglobulin light chains. Importantly, the same components also serve as an "amplification loop" following C3b fixation to targets through any of the 3 pathways (10), which is an essential mechanism for complement-dependent injury in vivo (11) .
During the processes of C3 activation by its convertases, the thioester bond in C3 is broken, allowing the formation of covalent ester or amide linkages from C3b to neighboring molecules (12) . The subsequent sequential cleavage of C3b to iC3b/C3dg by factor I and cofactors provides the capacity to interact with specific high-affinity/avidity C3 receptors (13) . The formation of C3b is followed by the formation of the multiprotein classical pathway and alternative pathway C5 convertases, C5 cleavage to C5b, and assembly of the pore-like membrane attack complex. Also generated through the convertase activation processes are the soluble anaphylatoxins C3a and C5a, which have multiple proinflammatory and complex immune regulatory roles (14) .
Receptors. High-affinity complement receptors are engaged by proteolytic cleavage fragments generated during the activation process. Receptors include complement receptor type 1 (CD35), a widely distributed molecule that acts as the major receptor on erythrocytes for binding and processing circulating immune complexes containing C3b and/or C4b, acts on B cells to modulate responses to antigens (15) , and functions on neutrophils and macrophages as a phagocytosis-promoting receptor (16) . A second receptor, which binds the iC3b and C3dg fragments, is CR2/CD21, a receptor expressed on B cells, epithelial cells, follicular dendritic cells (FDCs), thymocytes, and a subset of peripheral T cells. CR2 promotes B cell activation, traps and retains immune complexes on FDCs within lymphoid tissues, and serves as a modulator of B cell self-reactivity (15, 17) . CR3 and CR4 are integrins that bind iC3b, are expressed on phagocytes and FDCs, and exhibit immune regulatory roles (2) . Another receptor is complement receptor of the immunoglobulin superfamily, which is expressed on Kupffer cells and mediates clearance of targets from the circulation. The anaphylatoxic peptides, C5a and C3a, exhibit multiple proinflammatory properties, and are each recognized by C5a receptor (C5aR)/CD88 and C3aR, which are members of the rhodopsin family (18) . C5a is a particularly important molecule, demonstrating multiple proinflammatory properties, including leukocyte chemotaxis, aggregation of neutrophils and platelets, release of mast cell mediators, generation of leukotrienes, cytokines, and reactive oxygen metabolites, and activationmodulating cross-talk with IgG Fc receptors (19) . Similarly, C3a plays key roles in inflammatory disorders (20) .
Regulators. Several mechanisms are used to restrain complement activation. For example, the classical and lectin pathways are blocked by a C1 esterase inhibitor (C1-INH) (21) , which serves as a trap for C1r/ C1s and activated MASP-1/MASP-2. C1-INH also inactivates the proteases kallikrein, factor XIa, XIIa, and plasmin of the contact and clotting systems. In addition, membrane and circulating proteins accelerate the decay and inactivation of the C3 and C5 convertases (22) . These include factor I, which cleaves and inactivates/processes C3b and C4b at specific sites when they are either free in the fluid phase or target-bound. Factor H, a soluble inhibitor, is a decay accelerator of the alternative pathway and also serves as a cofactor for factor I-mediated cleavage of C3b. With regard to the classical pathway, C4b binding protein is a fluid-phase protein that exhibits mechanisms similar to those of factor H.
Proteins that block complement activation on the cell membrane include decay-accelerating factor (DAF; CD55), membrane cofactor protein (MCP; CD46), and membrane inhibitor of reactive lysis (CD59) (23) . DAF binds C3b or C4b and increases the spontaneous decay of both the classical pathway and alternative pathway C3 complexes. MCP serves as a cofactor for the cleavage of C3b and C4b into their inactive forms. CD59 binds C8 to block the effective incorporation of C9 and also blocks C9 polymerization, which is required for pore formation. Finally, C5a and C3a undergo a rapid loss of activity mediated by C-terminal cleavage of arginine by carboxypeptidase (24) .
Another type of regulatory activity is manifest by members of the complement factor H-related (CFHR) family, for which many associations with human diseases have been observed (25) . These conditions include agerelated macular degeneration (AMD), atypical hemolytic uremic syndrome (HUS), IgA nephropathy, and systemic lupus erythematosus (SLE). In this regard, some CFHR 2104 THURMAN ET AL members appear to act as inhibitors of factor H by blocking its binding to target surfaces, resulting in enhanced local complement activation.
Overview of complement therapeutic approaches
Only 2 anti-complement drugs are currently approved (26) . The first, eculizumab, is a humanized monoclonal antibody directed against C5 (27) , while the second encompasses a number of molecular versions of C1-INH (28) . Eculizumab is approved for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical HUS (29) , while C1-INH preparations are approved for the treatment of hereditary angioedema (HAE). In addition, therapeutics are being developed that are directed to molecules including the C3 and C5 convertases, C3 itself, C1s, MASP-2, MASP-3, properdin, factor D, factor B, C5, C5a, C3a, and C6 as a means to disrupt the membrane attack complex ( Figure 1 and Table 1 ). In addition to the soluble proteins, inhibitors of receptors are being evaluated. Therapeutic modalities include monoclonal antibodies, recombinant forms of natural inhibitors, small molecules with various backbones and structures, RNA-based drugs, other recombinant proteins, modular chimeric proteins, and gene therapy. In addition, tissue-or cell-targeted therapeutics are under development, with the goal of directing inhibitors more directly to sites of complement activation (30) .
Disease indications that are currently being evaluated include myasthenia gravis and neuromyelitis optica. Additional focus is on local delivery, especially into the eye for AMD, as well as C3 glomerulopathy, a disease characterized by associations with alternative pathway-activating mutations and autoantibodies (22) . Challenges in the development of complement inhibitors include the high levels of circulating proteins, which are much higher than cytokine levels. Additional challenges include the relatively rapid turnover, the acute-phase response-mediated increases in circulating factor levels, and the potent biologic activity of locally synthesized factors (26) . The risks inherent in the use of systemic complement inhibitors, especially long-term use, likely mirror the phenotypes seen in patients with homozygous Regenesance Preclinical * Due to the large number of rapidly evolving development programs, as well as the expanding list of indications that are under consideration, this list should not be considered complete but rather is illustrative of key features of the complement therapeutic pipeline. Additional molecular entities are described in ref. 26 . mAb = monoclonal antibody; C1-INH = C1 esterase inhibitor; HAE = hereditary angioedema; MASP-2 = mannosebinding lectin-associated serine protease 2; HUS = hemolytic uremic syndrome; AMD = age-related macular degeneration; PNH = paroxysmal nocturnal hemoglobinuria; siRNA = small interfering RNA.
complement deficiencies (31) and include disruption of immune complex processing, bacterial infection, and potentially the impairment of cellular regeneration and repair cycles. Practical experience in the area of infection risk mitigation has been gained through the clinical use of eculizumab and the means by which infection with Neisseria has been partially mitigated through longterm antibiotic treatment and/or close monitoring (27) .
Use of complement therapeutics in genetically defined and related diseases that are in the differential diagnosis with rheumatic diseases
There is a wealth of experimental data from animal models pointing to the importance of the complement system in causing cell and tissue damage (2) . However, the most important insights have been gained through human therapeutic trials for rare human diseases caused by mutations that directly affect the complement system.
Paroxysmal nocturnal hemoglobinuria. PNH was the first disease in which the major complementdependent aspects (red blood cell [RBC] lysis, platelet/ endothelial cell activation, and clotting) could be therapeutically blocked (27) . PNH is caused by somatic mutations in the gene PIGA that result in the absence of DAF/CD55 and CD59 on clonal populations and the subsequent inability of these lineages, especially RBCs, to control spontaneous alternative pathwaymediated complement activation. Treatment of patients with eculizumab markedly abrogates hemolysis and other associated clinical sequelae, inclusive of thrombotic events that were previously the primary cause of death (32) .
Antibody-mediated hemolytic syndromes. The complement system has long been thought to play important roles in these syndromes, especially cold agglutinin disease, in which activation of complement leads not primarily to direct lysis but rather to the clearance of IgM and C3 fragment-coated RBCs in the liver through a process designated extravascular hemolysis. Recent therapeutic development in this area has included the use of a monoclonal antibody inhibitor of C1s, which is demonstrating promise in studies in patients with cold agglutinin disease (33) . The approach of blocking complement activation through the classical pathway would also be appropriate to test in patients who demonstrate autoimmune hemolytic anemia.
Hereditary angioedema. HAE is associated with heterozygous mutations in the gene encoding C1-INH and has been treated with the purified protein obtained from plasma as well as antifibrinolytic agents and attenuated androgens (34) . Replacement therapy with recombinant C1-INH for HAE attacks has been approved, and this has also opened up potential opportunities for its use in other diseases.
Atypical HUS. Atypical HUS is a multiorgan disease caused by complement-mediated inflammation and thrombosis in the microvasculature. Patients typically present with thrombocytopenia, hemolytic anemia, and renal failure. Most cases of HUS (~90%) are caused by enteric infection with bacteria that produce Shiga-like toxin, and the term "atypical" is used to describe those patients in whom the disease develops in the absence of Shiga-like toxin-producing bacteria. The majority of patients with atypical HUS have genetic or acquired defects in their ability to control activation of the alternative pathway (35) . Disease-associated mutations have been identified in the genes for factor H, MCP, factor I, C3, factor B, and thrombomodulin. Mutations in the complement regulatory proteins impair complement regulation by the affected proteins, whereas mutations in the C3 and complement factor B genes are gain-of-function mutations. Some patients with atypical HUS have inhibitory autoantibodies that impair the ability of factor H to control activation of the alternative pathway (36). In 2 phase II studies of eculizumab in patients with atypical HUS (37), eculizumab treatment led to significant clinical improvement, and additional studies also confirmed that eculizumab is an effective treatment for this disease (38) .
Uveitis, AMD, and other ophthalmologic disorders. Based on extensive literature regarding experimental disease models (39), the complement system has been considered to play a major role in the pathogenesis of autoimmune uveitis. Additional impetus for studies of ophthalmologic disorders has been provided by the findings that informative polymorphisms and rare variants of complement genes are associated with a heightened risk for the development of AMD (40) .
Rheumatic diseases that are likely to be partly complement-dependent Rheumatoid arthritis (RA). RA affects 0.8-1.0% of the population and is associated with substantial personal and societal costs (41) . The pathogenesis of RA can be divided into 3 distinct phases: initiation, perpetuation, and chronic inflammation. Innate immune mechanisms involving the complement system are likely to be involved in each phase (42) . Studies have demonstrated the presence of IgG-containing immune complexes along with complement C3 activation fragments in >90% of patient cartilage samples 2106 THURMAN ET AL (43) , as well as extensive synovial complement deposition and synthesis (44) . Notably, an unbiased analysis of the epigenetics of RA fibroblast-like synoviocytes revealed that the complement system was among the top 6 pathways identified as being expanded in samples from RA patients (45) . Studies in murine models have revealed that complement is key to initiating, amplifying, and driving effector mechanisms (46) . In addition, cartilage-derived proteins in RA exhibit both complement-activating and complement-regulatory functions (47) . Experimental models have identified key roles for the alternative and lectin pathway initiation and amplification mechanisms, chemotactic peptides and their receptors, local complement synthesis, and release and dysregulation mechanisms on cartilage and cells. A mechanism-based model is shown in Figure 2 . With regard to adaptive immunity in RA, the CR2-C3dg interaction plays an important role in murine models, in which inhibition of the receptor leads to a decrease in clinical disease activity, tissue damage, and development of pathogenic anticollagen and other disease-specific autoantibodies (48) . Enthusiasm with regard to the use of complement inhibitors in RA has waned since the finding that C5aR blockade did not reduce synovial inflammation in RA patients (49) , although the increasing understanding of the immune complex mechanisms underlying the initial joint inflammation suggests that earlier treatment may be more effective (50) .
Systemic lupus erythematosus. The role of complement in SLE is paradoxical insofar as the complement system helps to prevent autoimmunity, yet it is also an important mediator of inflammationassociated tissue injury in SLE. Individuals with deficiencies of C1, C2, and C4 are all at increased risk of the disease (51) . The complement system is believed to prevent autoimmunity via several mechanisms. Intracellular antigens are released when cells die, and opsonization of the antigens by complement facilitates their rapid phagocytosis (52) , which may reduce the likelihood of an autoimmune response to the exposed self antigens. Complement activation may also improve B cell and T cell tolerance to self antigens (53) .
Once autoimmunity develops, circulating immune complexes deposit in tissue or form in situ when antibodies bind to tissue antigens. Deposited immune complexes activate the complement system, with several proinflammatory and cytotoxic effects (Figure 3) . It stands to reason that this inflammatory process causes more severe injury in patients with a reduced ability to control complement activation, and genetic studies suggest that this is the case (54) . Opsonization of injured cells with complement proteins may also amplify production of type I interferons (55) . Ideally, treatment regimens for patients with lupus would rapidly block the inflammatory effects of immune complexes within tissue and also modulate the adaptive immune responses that underlie autoantibody generation. A rational approach might therefore be to combine a complement inhibitor with drugs that target the adaptive immune response. This combination could prevent irreversible injury by immune complexes already deposited in tissue while awaiting the adaptive immune effects. Notably, eculizumab has been successfully used off-label in the setting of severe lupus nephritis, even in the absence of thrombotic microangiopathy lesions (56) , although no large series or trials have been conducted.
The optimal complement-inhibitory drug in SLE would block the pathogenic effects of complement without impairing its role in protecting against autoimmunity. This outcome could be achieved by selectively blocking the alternative pathway and by using drugs that are targeted to sites of tissue injury (30) .
Vasculitis. Several autoimmune diseases can present with small vessel vasculitis and glomerulonephritis.
Immunofluorescence microscopy of tissue biopsy specimens from patients with these diseases reveals prominent immunoglobulin and complement deposits. Tissue biopsy specimens obtained from patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), in contrast, display only small quantities of immune deposits ("pauci-immune"). Nevertheless, a growing body of experimental and clinical observations indicates that complement activation is critical to the development of ANCA-mediated disease.
A role of complement was first shown in a murine model of ANCA-associated vasculitis, in which complement depletion with cobra venom factor, factor B deficiency, and C5 deficiency were each protective (57) . In a subsequent study, the investigators observed that ANCAs cause neutrophil activation in vitro, and factors released from the neutrophils (including reactive oxygen species) caused generation of C5a when mixed with serum (58) . C5a, in turn, increased expression of ANCA antigens by neutrophils and primed them to respond to ANCAs. ANCAs thereby induce a feedback loop in neutrophils, and C5a is an essential intermediary. Using an in vivo model of AAV, the authors observed that mice with C5a receptor-deficient bone marrow developed significantly milder disease than mice with wild-type bone marrow. Although C3 deposits are less prominent in the glomeruli of patients with AAV than in the glomeruli of patients with immune complex diseases, they are detected in >40% of patients and correlate with poor outcomes (59) . In addition, the levels of complement activation fragments (Bb, C3a, C5a, and soluble C5b-9) are also elevated in the plasma and urine (60) of patients with active disease, indicating that the alternative pathway is activated. Based on the efficacy of CCX168 in the murine model and the evidence of complement activation in patients with vasculitis, a phase II trial of CCX168 was conducted (61) . This study randomized patients to 3 different treatments: standard therapy (corticosteroids plus cyclophosphamide), standard therapy with reduced prednisone dosing plus CCX168, or CCX168 used in lieu of corticosteroids. The rate of renal disease remission and the reduction in the Birmingham Vasculitis Activity Score (62) was greater in the groups that received CCX168, and additional studies are underway that will compare the efficacy of CCX168 with that of prednisone at inducing remission when the drugs are used in combination with either cyclophosphamide or rituximab.
Antiphospholipid syndrome (APS) and catastrophic APS (CAPS). APS is a clinical syndrome that is diagnosed by detection of these antibodies in patients in whom thrombotic events or recurrent fetal loss has occurred. CAPS refers to a syndrome in which multiple organs are affected, and it can lead to multiorgan failure or death. An important role of the complement system in APS was identified by several studies that used antibodies from patients with APS to cause pregnancy loss in mice (63) . These studies revealed critical involvement of the classical pathway, the lectin pathway, and C5a in the pathogenesis of APS. C5a and the membrane attack complex cause endothelial cell activation, adhesion molecule expression, cytokine release, and release of prothrombotic molecules such as tissue Figure 4 . Pathogenesis of antiphospholipid syndrome. Antiphospholipid antibodies bind to b 2 -glycoprotein I (b 2 GPI) in complex with phospholipids on the surface of endothelial cells. The antibodies activate the complement cascade, generating C5a and C5b-9. C5b-9 and C5a cause activation of endothelial cells, which then express adhesion molecules. Activated endothelial cells also release tissue factor and plasminogen activator inhibitor 1 (PAI-1), creating a hypercoagulable environment. C5a induces monocytes to release soluble vascular endothelial growth factor 1 (sVEGF-1) and neutrophils to release tumor necrosis factor (TNF). Thrombin and fibrinogen can also cause complement activation, perpetuating these proinflammatory and hemostatic processes.
factor and plasminogen activator inhibitor 1 (Figure 4 ). C5a also induces neutrophils to release tissue factor and induces monocytes to release soluble vascular endothelial growth factor 1 (64) . Because thrombin and fibrinogen catalyze complement activation, microvascular cross-talk between the complement and coagulation cascades is probable.
A previous study showed clinical evidence of complement activation in patients with APS, in whom C3 and C4 levels were lower and C3a and C4a levels were higher than those in control subjects (65) . There are now several case reports of patients with treatmentrefractory disease who were successfully treated with eculizumab. Recurrence of APS is common after kidney transplantation, particularly in patients with CAPS, and case series of high-risk CAPS patients who were prophylactically treated with eculizumab to prevent disease recurrence after renal transplantation have been published (66) .
Neuromyelitis optica. Neuromyelitis optica is associated with and likely is caused by the actions of complement-activating IgG autoantibodies to aquaporin 4, which act as major drivers in experimental injury models. In support of the notion that complement has a role in this disorder, autoantibody-positive patients have been successfully treated with eculizumab, as manifest by decreasing the number of attacks as well as achieving secondary end points (67) .
Complement system diagnostic approaches
Recognition of the role of complement in human diseases and interest in complement therapeutics have increased the need for robust complement analysis. The currently used complement diagnostic testing can be divided into 4 general categories: component protein levels, pathway function assays, activation marker levels in both the circulation and deposited on cells, and analysis of complement genetics. Table 2 shows suggested approaches to working-up patients with suspected diseases or to assure coverage of the pathway targeted by therapeutics. Assays of the levels of the complement components, particularly C3 and C4, are the most common complement tests and have proved useful for following a number of rheumatic disorders. However, these assays have shortcomings that should be considered, especially when readily available tests for the levels of complement components do not C1q autoantibodies in HUVS * Many of these tests will require a laboratory specializing in complement testing. The exact laboratories and their test menus are subject to change, so consultation with their send-out department or use of similar resources is recommended. PNH = paroxysmal nocturnal hemoglobinuria; HUS = hemolytic uremic syndrome; ELISA = enzyme-linked immunosorbent assay; CFH = complement factor H; FHR-1 = factor H-related protein 1; MCP = membrane cofactor protein; DGKE = diacylglycerol kinase ε; THBD = thrombomodulin; HAE = hereditary angioedema; C1-INH = C1 esterase inhibitor; AMD = age-related macular degeneration; TBD = to be determined; RA = rheumatoid arthritis; MBL-2 = mannose-binding lectin 2; OA = osteoarthritis; SLE = systemic lupus erythematosus; CP = classical pathway; CAP = catastrophic antiphospholipid syndrome; HUVS = hypocomplementemic urticarial vasculitis syndrome.
identify whether C3, for example, is intact or cleaved. In addition, because many of the complement components are acute-phase reactants, measured levels balance disease-related consumption against increased production (68) . The second and most historic category of assays is the functional assay, particularly of CH50. Interest in functional testing has increased with the advent of complement-inhibiting therapeutics, and new methodologies have been designed to simplify functional testing. For instance, historic hemolytic assays are now joined by assays that utilize engineered lysosomes, the disruption of which is measured by enzyme-linked immunosorbent assay-style assays that are more amenable to use in routine immunology laboratory testing. All functional assays represent appropriate screening approaches for the whole complement pathway, from activation through the terminal complex. However, if a functional assay is going to be used to assess a patient receiving complement therapeutics, it is important to note that standard assays require substantial dilution of patient serum, which may artificially dilute the drug that is being tested and yield a result that does not parallel the in vivo inhibition. The alternative pathway (AH50) hemolytic assay utilizes lower dilutions and could, therefore, be the better choice for following up patients receiving complement inhibitor.
The final class of protein-level analysis of complement testing is the measurement of complement activation markers. These include the split products that are produced during the cleavage cascade of complement activation, as well as testing the convertases and complexes that are also produced upon complement activation, which therefore have the potential to serve as markers of ongoing or uncontrolled activation. The markers may be measured in the circulation, using standard immunologic testing, or as deposited on cells, using flow cytometry. These tests may reveal the specific pathway involved or inhibited and the extent of complement modulation that is occurring. This has led to particular interest in the measurement of terminal complement complex soluble C5b-9 for monitoring of C5 inhibitors. The limited implementation of activation marker testing revolves around availability as well as the requirement for rapid processing and freezing of the specimens (69) . Specifically, because the complement system is very prone to ex vivo activation, activation markers can increase (or functions decrease) substantially if not handled properly and frozen quickly at À80°C (70) .
Interest in complement genetic testing has also increased. A number of novel mutations have been associated with atypical HUS as well as with C3G and overlapping patterns of AMD (72,73) (see Table 2 ). Because certain mutations in factor H, in particular, are clearly mechanistically connected to pathogenesis, complement genetic testing can aid in diagnosis and prognosis. In addition, pairing complement genetic testing with phenotypic testing can be informative in determining the biologic outcome of novel mutations. Finally, additional methods are being evaluated that will utilize imaging of local complement activation in vivo and will provide insights into the local levels of fixation (for review, see ref. 73) .
Although challenges in complement testing remain, such testing has great potential to aid in the diagnosis of the increasing number of complementassociated disorders identified. With the rapid development of more complement-specific therapeutics, testing will only expand, increasing the pressure for more laboratories to be able to perform complement testing. During this phase, it may be especially advisable to work with those specialized laboratories that are familiar with this still esoteric field of testing.
Conclusions
The field of complement therapeutics and diagnostics has entered a new phase of expanded importance in the treatment and diagnosis of human disease. Although the first phases of treatment have been limited to rare diseases, the development of additional therapeutics should open up the field to evaluation of inhibitors in more common rheumatic and autoimmune diseases. Both successful utilization of existing therapies as described in case reports of rheumatic diseases, as well as the long history of experimental and clinical association studies illustrating close relationships of complement activation with disease manifestations, bode well for future success in these endeavors.
